Pasithea Therapeutics (NASDAQ:KTTA) Announces Earnings Results, Beats Expectations By $0.01 EPS

Pasithea Therapeutics (NASDAQ:KTTA) posted its quarterly earnings data on Friday. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.01, FiscalAI reports.

Pasithea Therapeutics Price Performance

Shares of KTTA traded up $0.00 during mid-day trading on Friday, reaching $0.52. 2,355,348 shares of the company’s stock traded hands, compared to its average volume of 558,271. The stock has a market cap of $17.44 million, a P/E ratio of -0.33 and a beta of 0.39. The stock’s 50-day moving average is $0.48 and its two-hundred day moving average is $0.62. Pasithea Therapeutics has a 12 month low of $0.28 and a 12 month high of $2.06.

Analysts Set New Price Targets

KTTA has been the topic of several recent analyst reports. Zacks Research downgraded shares of Pasithea Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Pasithea Therapeutics in a report on Monday, September 21st. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $3.00.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp. is a biotechnology company focused on developing treatments for central nervous system (CNS) disorders. Its research has centered on novel therapies for conditions such as depression and other neuropsychiatric diseases, areas in which existing treatments may not provide adequate results for all patients. The company has also pursued psychedelic-based therapeutic approaches and related clinical-development programs. In addition to drug discovery, Pasithea has explored treatment-delivery activities, including ketamine-assisted therapy services through operations associated with its business.